consolidating in lower range

The company is currently in Phase II testing of ZYN002 for treatment of refractory epilepsy and osteoarthritis. It’s also in Phase I testing of ZYN002 for treatment of Fragile X syndrome. ZYN001 is still in preclinical testing for multiple indications as well.

Shares of ZYNE stumbled at the start of 2017 as the company announced a 2.8 million-share offering priced at $18 to raise cash for its research. But after the dip, investors have piled back in on high hopes that the infusion of cash will yield big results.

The risk here isn’t about sales trends or acquisitions at this point, but simply clinical trial data and typical volatility associated with drug approvals. But if you’re looking to play broader medical marijuana trends instead of dissecting federal marijuana laws, ZYNE is a great option – particularly given that its focus on synthetic alternatives may make it more attractive to some consumers or even more effective in its clinical results than naturally grown marijuana
EN English (IN)
EN English
EN English (UK)
DE Deutsch
FR Français
ES Español
IT Italiano
PL Polski
SV Svenska
TR Türkçe
RU Русский
PT Português
ID Bahasa Indonesia
MS Bahasa Melayu
TH ภาษาไทย
VI Tiếng Việt
JA 日本語
KO 한국어
ZH 简体中文
ZH 繁體中文
AR العربية
HE עברית
Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features House Rules Moderators Website & Broker Solutions Widgets Stock Charting Library Feature Request Blog & News FAQ Help & Wiki Twitter
Profile Profile Settings Account and Billing My Support Tickets Contact Support Ideas Published Followers Following Private Messages Chat Sign Out